FDA Announces Joint Meeting of Drug Safety and Psychopharmacologic Advisory Committees

Summary

The FDA is hosting a joint meeting of its Drug Safety and Risk Management Advisory Committee and Psychopharmacologic Drugs Advisory Committee to provide public advice on regulatory issues, with a public comment period to follow.